In a patient with Burkitt lymphoma receiving B‑CHOP chemotherapy who has hyperkalemia, hypocalcemia, hyperphosphatemia, and normal uric acid, what is the most appropriate management?

Sevelamer (Phosphate Binder) is the Most Appropriate Management

In this patient with Burkitt lymphoma receiving B-CHOP chemotherapy who has hyperkalemia, hypocalcemia, and hyperphosphatemia but normal uric acid, the priority is managing the severe hyperphosphatemia with a phosphate binder like sevelamer (Option D).

Clinical Reasoning

This patient is experiencing tumor lysis syndrome (TLS) with a critical electrolyte pattern:

• Hyperphosphatemia (the dominant problem requiring immediate attention)
• Hypocalcemia (secondary to hyperphosphatemia via calcium-phosphate precipitation)
• Hyperkalemia (5.3 mEq/L - mild elevation)
• Normal uric acid (below 480 μmol/L or ~8 mg/dL)

Why Sevelamer (Option D)?

The hyperphosphatemia is the central metabolic derangement driving this patient's complications. Severe hyperphosphatemia causes calcium-phosphate precipitation in renal tubules, leading to acute kidney injury, and worsens hypocalcemia 1. Historical data from Burkitt lymphoma patients shows that hyperphosphatemia develops in 31% of non-azotemic patients and all azotemic patients after chemotherapy, and represents an additional criterion for dialysis consideration 1.

Phosphate binders such as aluminum hydroxide and aluminum carbonate are specifically recommended for treating hyperphosphatemia in TLS 2. Sevelamer serves this exact function by binding dietary and endogenous phosphate in the GI tract, preventing absorption and reducing serum levels.

Why NOT the Other Options?

Allopurinol (Option C) is inappropriate because:

• The patient's uric acid is already normal/controlled
• Allopurinol only prevents formation of new uric acid; it does not reduce existing uric acid or address hyperphosphatemia 3
• The guideline explicitly states that for patients with preexisting hyperuricemia >450 μmol/L (7.5 mg/dL), rasburicase is preferred over allopurinol 3
• This patient doesn't have hyperuricemia, making allopurinol unnecessary

Lasix/Furosemide (Option A) is contraindicated because:

• Loop diuretics can worsen hyperkalemia by causing volume depletion and reduced renal potassium excretion
• The patient has no mention of volume overload or inability to urinate
• Diuretics should only be used to maintain urine output of 80-100 mL/m²/h if hydration alone is insufficient 3

Thiazide (Option B) is inappropriate because:

• Thiazides can worsen hypocalcemia
• They don't address the primary problem of hyperphosphatemia
• No role in acute TLS management

The Pathophysiology Connection

The triad of hyperphosphatemia, hypocalcemia, and hyperkalemia without hyperuricemia indicates:

1. Successful uric acid prophylaxis (likely received allopurinol or rasburicase already)
2. Ongoing massive cell lysis releasing intracellular phosphate and potassium
3. Calcium-phosphate precipitation causing the hypocalcemia and threatening renal function

Recent case reports confirm that in the era of aggressive allopurinol/rasburicase prophylaxis, nephrologists increasingly witness divalent cation abnormalities (phosphate, calcium) without marked uric acid elevation 4. Extreme hyperphosphatemia (up to 21.4 mg/dL) can occur and requires aggressive management 4.

Clinical Pitfalls to Avoid

• Do not give calcium supplementation aggressively when phosphate is elevated - this risks metastatic calcification and worsening renal function
• Do not use sodium bicarbonate for alkalinization when phosphate levels are elevated, as it promotes calcium-phosphate precipitation 3
• Monitor for dialysis indications: If phosphate rises rapidly and exceeds 5 mmol/L (~15 mg/dL), creatinine exceeds 200 μmol/L, or potassium exceeds 6 mmol/L with severe clinical signs, hemodialysis becomes necessary 5

The mild hyperkalemia (5.3) can be monitored and managed supportively while addressing the hyperphosphatemia, which is the root cause of the metabolic derangements in this TLS presentation.